Your browser doesn't support javascript.
loading
C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study.
Xu, Wen-Hao; Wang, Jun; Huo, Da-Zhu; Yin, Guo-Cai; Cao, Da-Long; Shi, Guo-Hai; Qu, Yuan-Yuan; Ye, Ding-Wei; Zhang, Hai-Liang.
Afiliación
  • Xu WH; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China (mainland).
  • Wang J; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China (mainland).
  • Huo DZ; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China (mainland).
  • Yin GC; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China (mainland).
  • Cao DL; Department of Research Management, Fudan University Shanghai Cancer Center, Shanghai, China (mainland).
  • Shi GH; Clinical Medicine, Jining Medical University, Jining, Shandong, China (mainland).
  • Qu YY; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China (mainland).
  • Ye DW; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China (mainland).
  • Zhang HL; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China (mainland).
Med Sci Monit ; 25: 8984-8994, 2019 Nov 26.
Article en En | MEDLINE | ID: mdl-31769434
ABSTRACT
BACKGROUND This study aimed to evaluate the factors associated with a survival benefit for patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib, with and without cytoreductive nephrectomy (CN). MATERIAL AND METHODS This retrospective clinical study included 118 patients with mRCC who were treated with CN and sunitinib (CN-sunitinib) (N=70) and with sunitinib-alone (N=48). Categorical clinicopathological variables were compared with hypothesis tests using contingency tables and a chi-squared test. Independent indicators for progression-free survival (PFS) and overall survival (OS) were analyzed with univariate and multivariate Cox regression models. The Kaplan-Meier method and log-rank test were used to evaluate patient survival. RESULTS The median PFS and OS for the 118 patients were 8.38 and 15.48 months, respectively. There were no significant differences between the CN-sunitinib group and the sunitinib-alone group for either PFS (7.2 months vs. 11.6 months; P=0.525) or OS (16.7 months vs. 15.2 months; P=0.839). Stratification of patients based on clinicopathological characteristics showed that CN was significantly associated with reduced PFS and OS for patients with lymph node metastasis (PFS, P<0.001; OS, P<0.001) and high International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk scores (PFS, P=0.003; OS, P=0.011). However, CN was associated with a significant survival benefit for patients with low levels of serum C-reactive protein (CRP<10 mg/L) (PFS, P=0.026; OS, P=0.007). CONCLUSIONS Sunitinib-alone without CN improved the survival of patients with mRCC who had high IMDC risk scores or lymph node metastasis. CN and sunitinib resulted in significantly improved survival in patients with low serum CRP.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteína C-Reactiva / Carcinoma de Células Renales / Sunitinib Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Med Sci Monit Asunto de la revista: MEDICINA Año: 2019 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proteína C-Reactiva / Carcinoma de Células Renales / Sunitinib Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Asia Idioma: En Revista: Med Sci Monit Asunto de la revista: MEDICINA Año: 2019 Tipo del documento: Article